SBS 2007 Technical Conference Sessions on CD-ROM now Available
News Jul 26, 2007
If you missed any part of the 2007 Society for Biomolecular Sciences Annual Conference or you would like to share special highlights with your colleagues, you can do so by ordering all or some conference sessions on CD-ROM.
Continue to learn from the experts who presented sessions ranging from the Opening Keynote Sessions entitled, Human Cell Systems Biology for Drug Discovery: Applications to Drug Innovation & Development from Screening to Indication Selection, and Everyone Depends on Everyone Else to the final session on Thursday - Advances in Screening (Part III.)
The last sessions included-Plate-based, Label-free Biosensors not a Panacea, also Indispensible (the Plenary session), followed by Potent and Selective Antagonists Validate TRVP3 as a Target for Analgesic Therapeutics, In Vivo Compound Screening in Automated Z-TagSM Zebrafish Cardiotoxicity & Angiogenesis Assays, Targeting Ion Channels in High-throughput Screening, and ending with Fragment Screening of Drug Targets by Biophysical Assays & Structural Analysis.
The last-day CD also covers the Point/Counterpoint Discussion, pitting Mel Reichman against Chris Lipinski, as they tackled the subject - The NIH Roadmap as a New Model for Drug Discovery: Pipelines or Pipedreams.
This is followed by the 2007 Achievement Award Lecture by Dr. Eric Lander: Beyond the Human Genome Project, and the Closing Keynote, by Dr. Larry Gold, - Molecular Diagnostics: Improved Health & Lower Healthcare Costs.
Go back in time and listen to the presenters from the 13th Annual SBS Conference & Exhibition.
If you missed any or all of the technical sessions offered in Montreal, fill that learning gap with your own set of CD-ROMs. Get thee entire four-day CD or choose just one specific day.
Each CD consists of a full day of concurrent presentations. Order forms are obtained by going to the special SBS website – http://www.softconference.com/070415
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.